Innovative Medicine: nipocalimab in gMG; RYBREVANT Sub-Q in NSCLC; TREMFYA Sub-Q in UC; TAR-200 NMIBC; icotrokinra in PsO and UC; RYBREVANT in HNC; CAPLYTA in aMDD. MedTech: OTTAVA progression; ...

In-Market Brands: RYBREVANT + LAZCLUZE: Current 2027 / 2028 market estimates for specific product sales: approx. $1.8B/$2.3B. Internal forecast vs. current 2027 /2028 market estimates: 2x higher.

Innovative Medicines: Expect more pronounced impact from newly launched products as the year progresses; STELARA biosimilar competition to accelerate; HUMIRA erosion curve remains the best proxy; ...

General Motors (GM) has faced its fourth analyst downgrade so far in April, reflecting growing concerns over the automaker’s ability to manage ...

Baird analyst Michael Ha lowered the firm’s price target on Centene (CNC) to $69 from $71 and keeps a Neutral rating on the shares. The firm ...

The auto supply chain is vast and spans numerous countries across the world, so any tariffs would have a knock-on impact on ...

Allied is a leading owner-operator of distinctive urban workspace in Canada’s major cities. Allied’s mission is to provide knowledge-based organizations with workspace that is sustainable and ...

Key highlights from the 2025 AI Governance and Data Privacy Jobs Report include: Contract-to-Hire Takes the Lead: 2024 marked the first year that contract and contract-to-hire staffing outpaced direct ...

Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s ...

Palantir Technologies (PLTR) stock rose more than 4% in yesterday’s session after the company sold its AI-based military system, the Maven ...

Baird analyst Michael Ha downgraded Agilon Health (AGL) to Neutral from Outperform with a price target of $5, down from $6. The firm sees ...

Reports Q3 revenue $15.09M vs. $8.28M last year. “Our quarterly results reflect sustained commercial momentum as Kestra grows and penetrates ...